Welcome, fellow medical investor. I'm not quite sure what your points are other than that it is indeed difficult to develop a HSV-1 vaccine. The preclinical studies on mice were and are absolutely necessary before progressing Phase 1 trials on humans. As for the 'very small' sample sizes, 20-25 subjects is standard for Phase 1 and definitely statistically significant. So I really don't know why you brought up either points. But I do agree that if there is a robust immune response in Phase II trials, Professor Frazer has won the global research race to cure HSV-1. I reckon he's got this. :)
updated ballieu report - target range 25-55c, page-43
-
- There are more pages in this discussion • 25 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.40 |
Change
0.310(2.05%) |
Mkt cap ! $325.5M | |||
| Open | High | Low | Value | Volume |
| $15.57 | $15.84 | $15.15 | $452.1K | 29.37K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1000 | $15.15 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.40 | 2886 | 1 |
View Market Depth
| Last trade - 16.10pm 21/08/2024 (20 minute delay) ? |
| AVR (ASX) Chart |